Needham raised the firm’s price target on Geron to $5 from $4 and keeps a Buy rating on the shares. The AdComm voted 12-2 in favor of imetelstat’s benefit/risk profile, and due to the nearly unanimous vote, the company’s imetelstat will receive the go-ahead on or prior to its June 16th PDUFA date, the analyst tells investors in a research note.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on GERN:
- FDA Oncologic Drugs Advisory Committee holds virtual meeting
- B. Riley sees closely contested vote after ‘hair-raising’ Geron briefing docs
- FDA says ‘not clear’ magnitude, durability of RBC-TI outweighs Geron drug risks
- Needham biotechnology analyst to hold an analyst/industry conference call
- Geron price target lowered to $4.50 from $5 at Baird
